TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Apple Turns 50: From Garage Startup to AI Crossroads 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Britain Courts Anthropic Amid US Defense Department Dispute 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
MENLO PARK, Calif., July 27, 2017 -- Corium International, Inc. (NASDAQ:CORI) today announced that it will report financial results for the third quarter ended June 30, 2017 on Thursday, August 3, 2017 after the close of the U.S. financial markets. Corium will host a conference call and live audio webcast at 5:00 p.m. Eastern time, 2:00 p.m. Pacific time to discuss its financial results and report on recent progress.
Conference Call and Webcast Details
Investors and analysts can access the call toll-free by dialing (844) 831-3024 (United States) or +1 (315) 625-6887 (international). The conference ID# is 58879021. The conference call will also be available via a live audio webcast which may be accessed here, or by visiting the Investors section of Corium's website at http://ir.coriumgroup.com/events.cfm. The webcast will be archived on the Corium website for two weeks following the presentation.
About Corium
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Mayne Pharma and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. In addition to its proprietary Alzheimer's program, the company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics and additional transdermal products that are being developed with other partners. For further information, please visit www.coriumintl.com.
Corplex™ and MicroCor® are registered trademarks of Corium International, Inc.
Source: Corium
Investor and Media Contact: SMP Communications Susan Pietropaolo [email protected] (201) 923-2049
